García Lorenzo Jacinto, Montoro Martínez Victoria, Rigo Quera Antonio, Codina Aroca Alberto, López Vilas Montserrat, Quer Agustí Miquel, León Vintró Xavier
Servicio de Otorrinolaringología, Hospital de la Santa Creu i Sant Pau, c/Mas Casanovas 90, 08041, Barcelona, Spain.
Servicio de Otorrinolaringología, Hospital de Mollet, Mollet del Vallés, Spain.
Eur Arch Otorhinolaryngol. 2017 Sep;274(9):3449-3455. doi: 10.1007/s00405-017-4639-z. Epub 2017 Jun 17.
In the last decades, the treatment schemes for patients with locally advanced laryngeal cancer have changed significantly. These changes may have an impact in the survival of these patients. Our objective is to review the treatments administered to patients with locally advanced larynx tumors during a period of 30 years in our institution and to evaluate the prognostic impact of the changes in treatment protocols. Retrospective analysis of a cohort of 830 consecutive patients with T3 or T4 laryngeal carcinomas diagnosed and treated between 1985 and 2014 with a minimum follow-up of 1.5 years. During the study period, we witnessed a reduction in surgery as the initial treatment, as well as a substitution of induction chemotherapy by chemoradiotherapy as an organ preservation strategy. For patients with T3 tumors, there were no differences in cancer-specific survival by type of treatment, while patients with T4 tumors treated surgically showed significantly better survival than those treated with preservation strategies. Patients treated in the last decade (2005-2014) showed worse cancer-specific survival than those treated in the previous decade (1995-2004). The multivariate analysis showed significant differences in cancer-specific survival for larger tumors, positive nodal extension, and treatment with radiotherapy alone. The main changes in the management of advanced laryngeal carcinomas are the implementation of organ preservation strategies that reduce the use of surgery and the progressive of chemoradiotherapy as a standard treatment. These changes may have had a negative impact in survival of these patients.
在过去几十年中,局部晚期喉癌患者的治疗方案发生了显著变化。这些变化可能会对这些患者的生存产生影响。我们的目的是回顾我们机构在30年期间对局部晚期喉肿瘤患者实施的治疗,并评估治疗方案变化的预后影响。对1985年至2014年间连续诊断和治疗的830例T3或T4喉癌患者进行回顾性分析,随访时间至少为1.5年。在研究期间,我们发现作为初始治疗的手术减少了,同时作为器官保留策略,诱导化疗被放化疗所取代。对于T3肿瘤患者,不同治疗方式的癌症特异性生存率没有差异,而接受手术治疗的T4肿瘤患者的生存率明显高于接受保留策略治疗的患者。在过去十年(2005 - 2014年)接受治疗的患者的癌症特异性生存率低于前十年(1995 - 2004年)接受治疗的患者。多因素分析显示,较大肿瘤、阳性淋巴结转移以及单纯放疗治疗在癌症特异性生存率方面存在显著差异。晚期喉癌治疗管理的主要变化是实施了减少手术使用的器官保留策略以及放化疗逐渐成为标准治疗方法。这些变化可能对这些患者的生存产生了负面影响。